RxDoctor Payments Data

Bhuvnesh Aggarwal, MD

Interventional Cardiology · Springfield, ILNPI 1760770101

Payments from drug & device makers

$17,700in general payments, 2019–2025

Across 220 payments — averaging $80.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Edwards Lifesciences$2K
  • Boston Scientific$2K
  • Abbott$2K
  • Philips North America LLC$629
  • Amgen$566
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$12,93073%
  • Food & beverage$4,75627%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,700 in reported general payments places this provider in the 65th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$465,485
Medicare patients
3,097
Services billed
8,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,001$1,062,268
XareltoRivaroxaban375$417,005
JardianceEmpagliflozin360$274,737
Repatha SureclickEvolocumab278$263,663
EntrestoSacubitril/Valsartan145$166,991
Praluent PenAlirocumab112$98,618
BrilintaTicagrelor106$89,282
FarxigaDapagliflozin Propanediol65$64,580
Repatha PushtronexEvolocumab68$64,392
Repatha SyringeEvolocumab27$18,220
Dofetilide20$14,423
Metoprolol Succinate1,197$13,244
Atorvastatin Calcium810$6,835
Rosuvastatin Calcium533$5,365
ClopidogrelClopidogrel Bisulfate554$5,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$109$1,062,2681,001 claims
Johnson & JohnsonXarelto$273$417,005375 claims
Boehringer IngelheimJardiance$98$274,737360 claims
NovartisEntresto$264$166,991145 claims
AstraZenecaBrilinta, Farxiga$64$153,862171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →